-
Price Momentum
IRLA is trading near the bottom of its 52-week range and below its 200-day simple moving average.
-
Price change
The price of IRLA shares has increased $1.22 since the market last closed. This is a 3.81% rise.
-
Opened at $31.17.
The stock opened $0.86 lower than its previous close.
Key terms
About IRLA
IRulya Therapeutics, Inc. is a biopharmaceutical company, which engages in unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes eDSP, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
-
Market cap: $32.58M
A market capitalization up to $300 million places IRLA in the micro-capitalization category.
Key terms
IRLA Financials
-
IRLA total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: -$83.98M (1Y), -$75.49M (Q2)
Net Income decreased 47.78% since last year and decreased 310.2% since last quarter.
-
Earnings per share: -$335.27 (1Y), -$12.31 (Q2)
EPS decreased 27.62% since last year and decreased 115.75% since last quarter.
Key terms
IRLA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IRLA Competitors
-
How competitors are chosen
IRLA's competitors are included in the Health Technology sector and Biotechnology group
-
Market cap: $32.58M
A market capitalization up to $300 million places IRLA in the micro-capitalization category.
Key terms
Latest investing news
-
Nasdaq sinks more than 2% as investors raise questions about AI debt -
A hidden risk appears to be building up in the markets. No one knows exactly what it means -
AI stocks drop after hot inflation report bolsters bets for Fed rate hikes -
Bank of America fined $1.2 billion by Treasury Department for violating money laundering and sanctions laws
